Sponsor:
VLP Therapeutics
Code:
NCT06736379
Conditions
Head and Neck Cancers- Squamous Cell
Head and Neck Cancer
Solid Tumors
HNSCC
SCC - Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)
Pembrolizumab (KEYTRUDA®)
VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by VLP Therapeutics on 2025-05-18.